1,845 Shares in Zoetis Inc. (NYSE:ZTS) Purchased by Blossom Wealth Management

Blossom Wealth Management acquired a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,845 shares of the company's stock, valued at approximately $301,000.

Other institutional investors have also modified their holdings of the company. Cherry Creek Investment Advisors Inc. increased its position in Zoetis by 2.0% during the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company's stock worth $590,000 after purchasing an additional 58 shares during the last quarter. Grove Bank & Trust increased its position in Zoetis by 0.5% during the third quarter. Grove Bank & Trust now owns 11,763 shares of the company's stock worth $2,298,000 after purchasing an additional 61 shares during the last quarter. Hancock Whitney Corp increased its position in Zoetis by 0.3% during the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company's stock worth $3,628,000 after purchasing an additional 61 shares during the last quarter. Strategy Asset Managers LLC grew its stake in Zoetis by 3.5% during the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company's stock worth $356,000 after buying an additional 62 shares during the period. Finally, Procyon Advisors LLC grew its stake in Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock worth $768,000 after buying an additional 63 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Up 0.2 %

NYSE ZTS traded up $0.30 during trading hours on Tuesday, reaching $172.24. 2,696,175 shares of the company traded hands, compared to its average volume of 2,685,644. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $77.71 billion, a PE ratio of 32.38, a PEG ratio of 2.72 and a beta of 0.90. The company has a 50 day moving average of $169.48 and a two-hundred day moving average of $179.39.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the prior year, the firm posted $1.36 EPS. The firm's revenue was up 11.6% compared to the same quarter last year. As a group, equities analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.16%. This is an increase from Zoetis's previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis's dividend payout ratio is 37.59%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ZTS shares. Leerink Partners started coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an "outperform" rating and a $215.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a research note on Friday, October 11th. Stifel Nicolaus decreased their target price on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a "neutral" rating and a $196.00 target price for the company. Finally, Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $215.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.